Global Valsartan-Hydrochlorothiazide Market 2023-2030

    In Stock

    Coming Soon




    A combo drug called valsartan-hydrochlorothiazide is used to treat high blood pressure. (hypertension). Valsartan, a member of the angiotensin receptor blocker (ARB) class of medications, and hydrochlorothiazide, a diuretic or “water pill,” are its two active components.


     While hydrochlorothiazide aids in lowering the body’s salt and water content, which also decreases blood pressure, valsartan acts by relaxing blood vessels to lower blood pressure.


    This drug should be taken at the same time every day, once daily, with or without meals. It’s crucial to adhere to your doctor’s dosage recommendations and to never stop taking this medicine without first talking to your doctor.


    Dizziness, headaches, weariness, and increased urination are typical adverse effects of valsartan-hydrochlorothiazide. Additionally, some people may get more severe adverse effects from it, such as kidney issues or allergic responses.


    Before beginning therapy with valsartan-hydrochlorothiazide, it is crucial to discuss any potential dangers and benefits with your doctor. This is true of any medicine.




    infographic: Valsartan-Hydrochlorothiazide Market, Valsartan-Hydrochlorothiazide Market Size, Valsartan-Hydrochlorothiazide Market Trends, Valsartan-Hydrochlorothiazide Market Forecast, Valsartan-Hydrochlorothiazide Market Risks, Valsartan-Hydrochlorothiazide Market Report, Valsartan-Hydrochlorothiazide Market Share


    Global valsartan-hydrochlorothiazide market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.



    Exforge HCT (amlodipine, valsartan, hydrochlorothiazide), the only blood pressure (BP) treatment that combines three drugs in a single pill, has been approved by the US Food and Drug Administration (FDA).


    Exforge HCT is a crucial new alternative for individuals who have tried using dual combinations of these blood pressure drugs without success. It combines the most commonly prescribed calcium channel blocker, angiotensin receptor blocker, and diuretic in one pill.


    Patients with moderate to severe hypertension can experience proven success with Exforge HCT. In a clinical trial, the maximum dose of Exforge HCT (amlodipine/valsartan/hydrochlorothiazide 10 mg/320 mg/25 mg) significantly reduced systolic and diastolic blood pressure when compared to all dual combinations of its components at the same doses (valsartan/hydrochlorothiazide 320 mg/25 mg, amlodipine/valsartan 10 mg/320 mg.


    Exforge HCT significantly lowers systolic and diastolic blood pressure compared to valsartan/hydrochlorothiazide, amlodipine/valsartan, and amlodipine/hydrochlorothiazide by 7.6/5.0 mmHg, 6.2/3.3 mmHg, and 8.2/5.3 mmHg, respectively.


    There is also an unmeasured placebo impact in these outcomes. Ambulatory blood pressure monitoring revealed that Exforge HCT’s blood pressure-lowering impact persisted for the entire 24-hour period.



    • Novartis Pharmaceuticals
    • Mylan Pharmaceuticals 
    • Teva Pharmaceuticals 
    • Zydus Pharmaceuticals 
    • Lupin Pharmaceuticals 
    • Torrent Pharmaceuticals 
    • Aurobindo Pharma 



    1. How many valsartan-hydrochlorothiazide are manufactured per annum globally? Who are the sub-component suppliers in different regions?
    2. Cost breakup of a Global valsartan-hydrochlorothiazide and key vendor selection criteria
    3. Where is the valsartan-hydrochlorothiazide manufactured? What is the average margin per unit?
    4. Market share of Global valsartan-hydrochlorothiazide market manufacturers and their upcoming products
    5. Cost advantage for OEMs who manufacture Global valsartan-hydrochlorothiazide in-house
    6. key predictions for next 5 years in Global valsartan-hydrochlorothiazide market
    7. Average B-2-B valsartan-hydrochlorothiazide market price in all segments
    8. Latest trends in valsartan-hydrochlorothiazide market, by every market segment
    9. The market size (both volume and value) of the valsartan-hydrochlorothiazide market in 2023-2030 and every year in between?
    10. Production breakup of valsartan-hydrochlorothiazide market, by suppliers and their OEM relationship


    Sl no Topic
    1 Market Segmentation
    2 Scope of the report
    3 Abbreviations
    4 Research Methodology
    5 Executive Summary
    6 Introduction
    7 Insights from Industry stakeholders
    8 Cost breakdown of Product by sub-components and average profit margin
    9 Disruptive innovation in the Industry
    10 Technology trends in the Industry
    11 Consumer trends in the industry
    12 Recent Production Milestones
    13 Component Manufacturing in US, EU and China
    14 COVID-19 impact on overall market
    15 COVID-19 impact on Production of components
    16 COVID-19 impact on Point of sale
    17 Market Segmentation, Dynamics and Forecast by Geography, 2023-2030
    18 Market Segmentation, Dynamics and Forecast by Product Type, 2023-2030
    19 Market Segmentation, Dynamics and Forecast by Application, 2023-2030
    20 Market Segmentation, Dynamics and Forecast by End use, 2023-2030
    21 Product installation rate by OEM, 2023
    22 Incline/Decline in Average B-2-B selling price in past 5 years
    23 Competition from substitute products
    24 Gross margin and average profitability of suppliers
    25 New product development in past 12 months
    26 M&A in past 12 months
    27 Growth strategy of leading players
    28 Market share of vendors, 2023
    29 Company Profiles
    30 Unmet needs and opportunity for new suppliers
    31 Conclusion
    32 Appendix
      Your Cart
      Your cart is emptyReturn to Shop